BCOR-CCNB3 sarcoma arising in the pharynx

Auris Nasus Larynx. 2023 Aug;50(4):618-622. doi: 10.1016/j.anl.2022.04.012. Epub 2022 May 8.

Abstract

Reports on BCOR-CCNB3 sarcoma in the head and neck region are scarce, given their unknown etiology. An 18-year-old male patient presented a rapidly enlarging tumor extending from the right nasopharynx to the oropharynx. Histological examination showed a spindle cell sarcoma with BCOR-CCNB3 fusion detected by fluorescence in situ hybridization, and BCOR-CCNB3 was diagnosed. After three courses of alternating VDC-IE therapy, the patient underwent tumor resection based on the original tumor range with a minimal margin, using the mandibular swing technique. Radiation therapy (50.4 Gy) was administered postoperatively, followed by three additional courses of alternating VDC-IE therapy. The patient survived and showed no evidence of disease at 12 months postoperatively. BCOR-CCNB3 sarcoma is a chemotherapy-sensitive sarcoma, and conservative resection with a minimal margin that does not interfere with the treatment flow is preferable.

Keywords: BCOR-CCNB3 sarcoma; Chemotherapy-sensitive tumor; Ewing sarcoma; Fluorescence in-situ hybridization; VDC-IE therapy.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Biomarkers, Tumor
  • Cyclin B
  • Humans
  • In Situ Hybridization, Fluorescence
  • Male
  • Pharynx* / pathology
  • Proto-Oncogene Proteins / genetics
  • Repressor Proteins / genetics
  • Sarcoma* / genetics
  • Sarcoma* / surgery

Substances

  • Proto-Oncogene Proteins
  • Repressor Proteins
  • Biomarkers, Tumor
  • CCNB3 protein, human
  • Cyclin B
  • BCOR protein, human